Thymus transplantation for treatment of cancer: lessons from murine models

References

• Thomas ED. Landmarks in the development of hematopoietic cell transplantation. World J. Surg.24(7), 815–818 (2000).
   PubMedGoogle Scholar
• Bacigalupo A, Oneto R, Bruno B et al. Current results of bone marrow transplantation in patients with acquired severe aplastic anemia. Report of the European Group for Blood and Marrow Transplantation. On behalf of the Working Party on Severe Aplastic Anemia of the European Group for Blood and Marrow Transplantation. Acta Haematol.103(19), 19–25 (2000).
   PubMed Web of Science ®Google Scholar
• Burt RK, Abinun M, Farge-Bancel D et al. Risks of immune system treatment. Science328(5980), 825–826 (2010).
   PubMedGoogle Scholar
• Saba N, Flaig T. Bone marrow transplantation for nonmalignant diseases. J. Hematother. Stem Cell Res.11(2), 377–387 (2002).
   PubMedGoogle Scholar
• Ueno NT, Rizzo JD, Demirer T et al. Allogeneic hematopoietic cell transplantation for metastatic breast cancer. Bone Marrow Transplant.41(6), 537–545 (2008).
   PubMed Web of Science ®Google Scholar
• Ikehara S. A novel method of bone marrow transplantation (BMT) for intractable autoimmune diseases. J. Autoimmun.30(3), 108–115 (2008).
   PubMed Web of Science ®Google Scholar
• Kolb HJ, Schattenberg A, Goldman JM et al. European Group for Blood and Marrow Transplantation Working Party Chronic Leukemia. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood86(5), 2041–2050 (1995).
   PubMed Web of Science ®Google Scholar
• Ohmori I, Hayamizu K, Oishi K et al. Inhibition of tumor growth in immunocompromised hosts by restoring type-2 immunity using infusion of G-CSF-treated allogeneic CD8+ leukocytes. Cytokine32(6), 255–262 (2005).
   PubMedGoogle Scholar
• Russell NH, Byrne JL, Faulkner RD et al. Donor lymphocyte infusions can result in sustained remissions in patients with residual or relapsed lymphoid malignancy following allogeneic haemopoietic stem cell transplantation. Bone Marrow Transplant.36(5), 437–441 (2005).
   PubMed Web of Science ®Google Scholar
• Chao NJ. Graft-versus-host disease. The view point from the donor T cell. Biol. Blood Marrow Transplant.3(1), 1–10 (1997).
   PubMedGoogle Scholar
• Goulmy E, Schipper R, Blokland E et al. Mismatches of minor histocompatibility antigens between HLA-identical donors and recipients and the development of graft-versus-host-disease after bone marrow transplantation. N. Engl. J. Med.334(5), 281–285 (1996).
   PubMed Web of Science ®Google Scholar
• Murphy WJ, Blazar BR. New strategies for preventing graft-versus-host disease. Curr. Opin. Immunol.11(5), 509–515 (1999).
   PubMedGoogle Scholar
• Ishida T, Inaba M, Hisha H et al. Requirement of donor-derived stromal cells in the bone marrow for successful allogeneic bone marrow transplantation. Complete prevention of recurrence of autoimmune diseases in MRL/MP-lpr/lpr mice by transplantation of bone marrow plus bones (stromal cells) from the same donor. J. Immunol.152(6), 3119–3312 (1994).
   PubMed Web of Science ®Google Scholar
• Hosaka N, Nose M, Kyogoku M et al. Thymus transplantation, a critical factor for correction of autoimmune disease in aging MRL/+ mice. Proc. Natl Acad. Sci. USA93(16), 8558–8562 (1996).
   PubMedGoogle Scholar
• Kushida T, Inaba M, Takeuchi K et al. Treatment of intractable autoimmune disease in MRL/lpr mice using a new strategy for allogeneic bone marrow cells transplantation. Blood95(5), 1862–1868 (2000).
   PubMed Web of Science ®Google Scholar
• Kushida T, Inaba M, Hisha H et al. Intra-bone marrow injection of allogeneic bone marrow cells: a powerful new strategy for treatment of intractable autoimmune diseases in MRL/lpr mice. Blood97(10), 3292–3299 (2001).
   PubMed Web of Science ®Google Scholar
• Nishida T, Hosaka N, Takaki T et al. Allogeneic intra-BM-BMT plus adult thymus transplantation from same donor has benefits for long-term survival even after sublethal irradiation or low-dose BM cell injection. Bone Marrow Transplant.43(11), 829–837 (2009).
   PubMedGoogle Scholar
• Hashimoto F, Sugiura K, Inoue K et al. Major histocompatibility complex restriction between hematopoietic stem cells and stromal cells in vivo. Blood89(1), 49–54 (1997).
   PubMed Web of Science ®Google Scholar
• Sugiura K, Hisha H, Ishikawa J et al. Major histocompatibility complex restriction between hematopoietic stem cells and stromal cells in vitro. Stem Cells19(1), 46–58 (2001).
   PubMedGoogle Scholar
• Ikehara S. A novel strategy for allogeneic stem cell transplantation: perfusion method plus intra-bone marrow injection of stem cells. Exp. Hematol.31(12), 1142–1146 (2003).
   PubMedGoogle Scholar
• Blanc KL, Rasmusson I, Sundberg B et al. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet363(9419), 1439–1441 (2004).
   PubMedGoogle Scholar
• Moore NC, Anderson G, Smith CA et al. Analysis of cytokine gene expression in subpopulations of freshly isolated thymocytes and thymic stromal cells using semiquantitative polymerase chain reaction. Eur. J. Immunol.23(4), 922–927 (1993).
   PubMedGoogle Scholar
• Bodey B, Bodey B Jr, Siegel SE et al. Review of thymic hormones in cancer diagnosis and treatment. Int. J. Immunopharmacol.22(4), 261–273 (2000).
   PubMed Web of Science ®Google Scholar
• Ziegler SF, Liu YJ. Thymic stromal lymphopoietin in normal and pathogenic T cell development and function. Nat. Immunol.7(7), 709–714 (2006).
   PubMed Web of Science ®Google Scholar
• Sakaguchi S, Ono M, Setoguchi R et al. Foxp3+ CD25+ CD4+ natural regulatory T cells in dominant self-tolerance and autoimmune disease. Immunol. Rev.212, 8–27 (2006).
   PubMed Web of Science ®Google Scholar
• Trenado A, Charlotte F, Fisson S et al. Recipient-type specific CD4+CD25+ regulatory T cells favor immune reconstitution and control graft-versus-host disease while maintaining graft-versus-leukemia. J. Clin. Invest.112(11), 1688–1696 (2003).
   PubMed Web of Science ®Google Scholar
• Edinger M, Hoffmann P, Ermann J et al. CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation. Nat. Med.9(9), 1144–1150 (2003).
   PubMed Web of Science ®Google Scholar
• Hosaka N, Ryu T, Miyake T et al. Treatment of autoimmune diseases in MRL/lpr mice by allogeneic bone marrow transplantation plus adult thymus transplantation. Clin. Exp. Immunol.147(3), 555–563 (2007).
   PubMedGoogle Scholar
• Markert ML, Devlin BH, McCarthy EA. Thymus transplantation. Clin. Immunol.135(2), 236–246 (2010).
   PubMed Web of Science ®Google Scholar
• Markert ML, Devlin BH, Alexieff MJ et al. Review of 54 patients with complete DiGeorge anomaly enrolled in protocols for thymus transplantation: outcome of 44 consecutive transplants. Blood109(10), 4539–4547 (2007).
   PubMed Web of Science ®Google Scholar
• Cui W, Hosaka N, Miyake T et al. Analysis of tolerance induction using triple chimeric mice: major histocompatibility complex-disparate thymus, hemopoietic cells, and microenvironment. Transplantation85(8), 1151–1158 (2008).
   PubMedGoogle Scholar
• Steinman RM, Hawiger D, Nussenzweig MC. Tolerogenic dendritic cells. Annu. Rev. Immunol.21, 685–711 (2003).
   PubMed Web of Science ®Google Scholar
• Kamano C, Vagefi PA, Kumagai et al. Vascularized thymic lobe transplantation in miniature swine: thymopoiesis and tolerance induction across fully MHC-mismatched barriers. Proc. Natl Acad. Sci. USA101(11), 3827–3832 (2004).
   PubMedGoogle Scholar
• Nobori S, Shimizu A, Okumi M et al. Thymic rejuvenation and the induction of tolerance by adult thymic grafts. Proc. Natl Acad. Sci. USA103(50), 19081–19086 (2006).
   PubMedGoogle Scholar
• Duncan SR, Capetanakis NG, Lawson BR et al. Thymic dendritic cells traffic to thymi of allogeneic recipients and prolong graft survival. J. Clin. Invest.109(6), 755–764 (2002).
   PubMedGoogle Scholar
• Krampera M, Glennie S, Dyson J et al. Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigen-specific T cells to their cognate peptide. Blood101(9), 3722–3729 (2003).
   PubMed Web of Science ®Google Scholar
• Bartholomew A, Stutgeon C, Siatskas M et al. Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. Exp. Hematol.30(1), 42–48 (2002).
   PubMed Web of Science ®Google Scholar
• Nakamura K, Inaba M, Sugiura K et al. Enhancement of allogeneic hematopoietic stem cell engraftment and prevention of graft-versus-host diseases (GvHD) by intra-bone marrow-bone marrow transplantation plus donor lymphocyte infusion. Stem Cells22(2), 125–134 (2004).
   PubMed Web of Science ®Google Scholar
• Lee JW, Epardaud M, Sun J et al. Peripheral antigen display by lymph node stroma promotes T cell tolerance to intestinal self. Nat. Immunol.8(2), 181–190 (2007).
   PubMedGoogle Scholar
• Toge T, Oride M, Yanagawa E et al. Prognostic significance of lymphocyte proliferative responses to mitogens in gastric cancer patients. Jpn J. Surg.12(6), 424–428 (1982).
   PubMedGoogle Scholar
• Das SN, Khanna NN, Khanna S. A multiparametric observation of immune competence in breast cancer and its correlation with tumor load and prognosis. Ann. Acad. Med. Singapore14(2), 374–381 (1985).
   PubMedGoogle Scholar
• Adler A, Stein JA, Ben-Efraim S. Immunocompetence, immunosuppression, and human breast cancer. III. Prognostic significance of initial level of immunocompetence in early and advanced disease. Cancer45(8), 2074–2083 (1980).
   PubMed Web of Science ®Google Scholar
• Adkins B, Charyulu V, Sun QL et al. Early block in maturation is associated with thymic involution in mammary tumor-bearing mice. J. Immunol.164(11), 5635–5640 (2000).
   PubMedGoogle Scholar
• Mandal D, Bhattacharyya A, Lahiry L et al. Failure in peripheral immuno-surveillance due to thymic atrophy: importance of thymocyte maturation and apoptosis in adult tumor-bearer. Life Sci.77(21), 2703–2716 (2005).
   PubMedGoogle Scholar
• Carrio R, Lopez DM. Impaired thymopoiesis occurring during the thymic involution of tumor-bearing mice is associated with a down-regulation of the antiapoptotic proteins Bcl-XL and A1. Int. J. Mol. Med.23(1), 89–98 (2009).
   PubMed Web of Science ®Google Scholar
• Mandal D, Lahiry L, Bhattacharyya A et al. Tumor-induced thymic involution via inhibition of IL-7R α and its JAK-STAT signaling pathway: protection by black tea. Int. Immunopharmacol.6(3), 433–444 (2006).
   PubMed Web of Science ®Google Scholar
• Bronte V, Apolloni E, Cabrelle A et al. Identification of a CD11b+/Gr-1+/CD31+ myeloid progenitor capable of activating or suppressing CD8+ T cells. Blood96(12), 3838–3846 (2000).
   PubMed Web of Science ®Google Scholar
• Kusmartsev SA, Li Y, Chen SH. Gr-1+ myeloid cells derived from tumor-bearing mice inhibit primary T costimulation. J. Immunol.165(2), 779–785 (2000).
   PubMed Web of Science ®Google Scholar
• Terabe M, Matsui S, Park JM et al. Transforming growth factor-β production and myeloid cells are an effector mechanism through which CD1d-restricted T cells block cytotoxic T lymphocyte-mediated tumor immunosurveillance: abrogation prevents tumor recurrence. J. Exp. Med.98(11), 1741–1752 (2003).
   Google Scholar
• Hoffmann P, Edinger M. CD4+CD25+ regulatory T cells and graft-versus-host disease. Semin. Hematol.43(1), 62–69 (2006).
   PubMed Web of Science ®Google Scholar
• Kono K, Kawaida H, Takahashi A et al. CD4+CD25high regulatory T cells increase with tumor stage in patients with gastric and esophageal cancers. Cancer Immunol. Immuunother.55(9), 1064–1071 (2006).
   PubMed Web of Science ®Google Scholar
• Wolf D, Wolf AM, Rumpold H et al. The expression of the regulatory T cell-specific forkhead box transcription factor FoxP3 is associated with poor prognosis in ovarian cancer. Clin. Cancer Res.11(23), 8326–8331 (2005).
   PubMed Web of Science ®Google Scholar
• Verdeeguer A, Munoz A, Canete A et al. Long-term results of high-dose chemotherapy and autologous stem cell rescue for high-risk neuroblastoma patients: a report of the Spanish working party for BMT in children (Getmon). Pediatr. Hematol. Oncol.21(6), 495–504 (2004).
   PubMedGoogle Scholar
• Fefer A, Sullivan KM, Weiden P et al. Graft versus leukemia effect in man: the relapse rate of acute leukemia is lower after allogeneic than after syngeneic marrow transplantation. Prog. Clin. Biol. Res.244, 401–408 (1987).
   PubMedGoogle Scholar
• Saito TI, Rubio MT, Sykes M. Clinical relevance of recipient leukocyte infusion as antitumor therapy following nonmyeloablative allogeneic hematopoietic cell transplantation. Exp. Hematol.34(9), 1270–1276 (2006).
   Google Scholar
• Kawai T, Cosimi AB, Spitzer TR et al. HLA-mismatched renal transplantation without maintenance immunosuppression. N. Engl. J. Med.358(4), 353–361 (2008).
   PubMed Web of Science ®Google Scholar
• Gibbons C, Sykes M. Manipulating the immune system for anti-tumor responses and transplant tolerance via mixed hematopoietic chimerism. Immunol. Rev.223(1), 334–360 (2008).
   PubMedGoogle Scholar
• Porcheray F, Wong W, Saidman SL et al. B-cell immunity in the context of T-cell tolerance after combined kidney and bone marrow transplantation in humans. Am. J. Transplant.9(9), 2126–2135 (2009).
   PubMed Web of Science ®Google Scholar
• Miyake T, Hosaka N, Cui W et al. Adult thymus transplantation with allogeneic intra-bone marrow-bone marrow transplantation from same donor induces high thymopoiesis, mild graft-versus-host reaction and strong graft-versus-tumor effects. Immunology126(4), 552–564 (2009).
   PubMed Web of Science ®Google Scholar
• Hosaka N, Cui W, Zhang Y et al. Prolonged survival in mice with advanced tumors treated with syngeneic or allogeneic intra-bone marrow-bone marrow transplantation plus fetal thymus transplantation. Cancer Immunol. Immunother.59(7), 1121–1130 (2010).
   PubMedGoogle Scholar
• Ikehara S, Ohtsuki H, Good RA et al. Prevention of Type I diabetes in nonobese diabetic mice by allogeneic bone marrow transplantation. Proc. Natl Acad. Sci. USA82(22), 7743–7747 (1985).
   PubMed Web of Science ®Google Scholar
• Ikehara S, Good RA, Nakamura T et al. Rationale for bone marrow transplantation in the treatment of autoimmune diseases. Proc. Natl Acad. Sci. USA82(8), 2483–2487 (1985).
   PubMed Web of Science ®Google Scholar
• Ikehara S, Kawamura M, Takao F et al. Organ-specific and systemic autoimmune diseases originate from defects in hematopoietic stem cells. Proc. Natl Acad. Sci. USA87(21), 8341–8344 (1990).
   PubMed Web of Science ®Google Scholar
• Kushida T, Inaba M, Ikebukuro K et al. A new method for bone marrow cell harvesting. Stem Cells18(6), 453–456 (2000).
   PubMed Web of Science ®Google Scholar
• Kushida T, Inaba M, Ikebukuro K et al. Comparison of bone marrow cells harvested from various bones of cynomolgus monkeys at various ages by perfusion or aspiration methods: a preclinical study for human BMT. Stem Cells20(2), 1555–1162 (2002).
   Google Scholar
• Adachi Y, Oyaizu H, Taketani S et al. Treatment and transfer of emphysema by a new bone marrow transplantation method from normal mice to Tsk mice and vice versa. Stem Cells24(9), 2071–2077 (2006).
   PubMedGoogle Scholar
• Takada K, Inaba M, Ichioka N et al. Treatment of senile osteoporosis in SAMP6 mice by intra-bone marrow injection of allogeneic bone marrow cells. Stem Cells24(2), 399–405 (2005).
   PubMedGoogle Scholar
• Ueda Y, Inaba M, Takada K et al. Induction of senile osteoporosis in normal mice by intra-bone marrow-bone marrow transplantation from osteoporosis-prone mice. Stem Cells25(6), 1356–1363 (2007).
   PubMedGoogle Scholar